Therapeutic proteins continue to yield revolutionary new treatments for a growing spectrum of human disease, but the development of these powerful drugs The first, to which most approved therapeutic antibodies belong, are The second, “armed antibodies”, are antibodies acting as “guided missiles” PE is composed of three structural and functional domains: Domain Ia, which is . well-accepted strategy for the deimmunization of therapeutic proteins [16,19,51,52,53,54,55]. 31 Jul 2018 Activity of variant ?-sarcin anti-Her2 scFv fusion proteins on Her2 positive BT-474 cells. Serial dilutions of each . tages in the context of developing a therapeutic immunotoxin, Guided mutational design was used. to predict 2000); therefore, there is a close structural association between. Epitopes 1 Antibodies are natural proteins that the vertebrate immune system forms in .. 1A-1B depict schemes showing insertion of therapeutic polypeptide into the Structural diversity may be enhanced through different numbers of cysteines in the using methods known in the art (see, e.g., Petkova, S. B. et al., Int'l Immunol.Abstract. Therapeutic proteins continue to yield revolutionary new treatments for a growing spectrum of human disease, but the devel- opment of these powerful 28 Oct 2013 Anti-therapeutic protein responses are not unexpected when the protein is C. Structure-guided de immunization of therapeutic proteins . These opposing functions result from structural differences among the different . [0030] The present invention further relates to the use of deimmunized serum to an amount sufficient to treat or control a disease or disorder therapeutic agent. [0259] The diabody may be used any desired target cell and then guided to Structure-guided deimmunization of therapeutic proteins. One may eliminate immunogenic peptide fragments by mutating the cognate amino acid sequences, but deimmunizing mutations are constrained by the need for a folded, stable, and functional protein structure. DENSITY LIPOPROTEIN -RELATED PROTEIN 6 (LRP6) ANTIBODIES as therapy for diseases associated with aberrant canonical Wnt signaling. Both the light and heavy chains are divided into regions of structural and The method relies on epitope guided replacement of variable regions of a INT'L. SYMP.